These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21549797)

  • 21. Monitoring heparin anticoagulation in the acute phase response.
    Uprichard J; Manning RA; Laffan MA
    Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new plastic collection tube made of polyethylene terephtalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractionated heparin, and low molecular weight heparin).
    Toulon P; Ajzenberg N; Smahi M; Guillin MC
    Thromb Res; 2007; 119(2):135-43. PubMed ID: 16426667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma.
    Bhargava AS; Heinick J; Schöbel C; Günzel P
    Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
    Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
    Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters.
    Noveck RJ; Hubbard RC
    J Clin Pharmacol; 2004 May; 44(5):474-80. PubMed ID: 15102867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.
    Korte W; Jovic R; Hollenstein M; Degiacomi P; Gautschi M; Ferrández A
    Hamostaseologie; 2010 Nov; 30(4):212-6. PubMed ID: 21057708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.
    Atallah S; Liebl M; Fitousis K; Bostan F; Masud F
    Perfusion; 2014 Sep; 29(5):456-61. PubMed ID: 24570077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin.
    Newall F; Ignjatovic V; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P
    Thromb Haemost; 2010 May; 103(5):1085-90. PubMed ID: 20174762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter.
    Arcangeli A; Rocca B; Salvatori G; Ciancia M; De Cristofaro R; Antonelli M
    Thromb Res; 2010 Jul; 126(1):24-31. PubMed ID: 20185164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical use of unfractionated heparin therapy in children: time for change?
    Newall F; Ignjatovic V; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P
    Br J Haematol; 2010 Sep; 150(6):674-8. PubMed ID: 20629660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.
    De Kam PJ; Kruithof AC; van Lierop MJ; Moerland M; Dennie J; Troyer MD; Langdon RB; Gutstein DE; Burggraaf J; El Galta R
    Int J Clin Pharmacol Ther; 2014 Aug; 52(8):631-41. PubMed ID: 24800921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
    Linkins LA; Julian JA; Rischke J; Hirsh J; Weitz JI
    Thromb Res; 2002 Sep; 107(5):241-4. PubMed ID: 12479885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist.
    Cushing DJ; Cooper WD; Cohen ML; McVoy JR; Sobel M; Harris RB
    Eur J Pharmacol; 2010 Jun; 635(1-3):165-70. PubMed ID: 20307530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors Affecting the Discrepancy Between Coagulation Times on Extracorporeal Circulation Using Unfractionated Heparin in Children and Young Adults.
    Haga T; Misaki Y; Sakaguchi T; Akamine Y
    Clin Appl Thromb Hemost; 2024; 30():10760296241252838. PubMed ID: 38711321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus japonicus Selenka.
    Suzuki N; Kitazato K; Takamatsu J; Saito H
    Thromb Haemost; 1991 Apr; 65(4):369-73. PubMed ID: 1647552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients.
    Al-Sallami H; Newall F; Monagle P; Ignjatovic V; Cranswick N; Duffull S
    Br J Clin Pharmacol; 2016 Jul; 82(1):178-84. PubMed ID: 26972703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inaccuracy of a "spiked curve" for monitoring unfractionated heparin therapy.
    Gausman JN; Marlar RA
    Am J Clin Pathol; 2011 Jun; 135(6):870-6. PubMed ID: 21571960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.